Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?
American Journal of Hematology · 2026-12 · 101 (12) · 3052-3053
DOI: 10.1002/ajh.70493 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 13.09.2026. Verfasst von Wenqiang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zibo Central Hospital, Zibo, People's Republic of China. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Zibo Central Hospital, Zibo, People's Republic of China.
- Department of Respiratory Medicine, Zibo Central Hospital Affiliated to Shandong Medical and Pharmaceutical University, Zibo, China.
ORCID-Profile: Zhenzhen Chen
Zitieren
APA
Chen, W., Ma, Q., & Chen, Z. (2026). Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?. American Journal of Hematology, 101(12), 3052-3053. https://doi.org/10.1002/ajh.70493
Vancouver
Chen W, Ma Q, Chen Z. Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?. American Journal of Hematology. 2026;101(12):3052-3053. doi:10.1002/ajh.70493
BibTeX
@article{Chen2026,
author = {Chen, Wenqiang and Ma, Qiuhong and Chen, Zhenzhen},
title = {Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {12},
pages = {3052--3053},
doi = {10.1002/ajh.70493}
}
EUVIMED